Fludarabine (Flu) and IV busulfan (Bu)±ATG:: Low toxicity conditioning regimen for stem cell transplantation (SCT) in AML and MDS -: Preliminary results.

被引：0
|
作者：
deLima, M
Shahjahan, M
Madden, T
Tran, HT
Gajewski, JL
Couriel, DR
Giralt, S
Donato, ML
Anderlini, P
Korbling, M
Khouri, I
Russell, JA
Champlin, RE
Andersson, BS
机构：
[1] Univ Texas, MD Anderson Canc Ctr, Houston, TX 77030 USA
[2] Tom Baker Canc Clin, Dept Med, Calgary, AB, Canada
来源：
BLOOD | 2001年 / 98卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
5147
引用
收藏
页码：345B / 345B
页数：1
相关论文
共 50 条
  • [41] A conditioning regimen of busulfan, fludarabine, and melphalan for allogeneic stem cell transplantation in children with juvenile myelomonocytic leukemia
    Yabe, Miharu
    Sako, Masahiro
    Yabe, Hiromasa
    Osugi, Yuko
    Kurosawa, Hidemitsu
    Nara, Taemi
    Tokuyama, Mika
    Adachi, Souichi
    Kobayashi, Chie
    Yanagimachi, Masakatsu
    Ohtsuka, Yoshitoshi
    Nakazawa, Yozo
    Ogawa, Chitose
    Manabe, Atsushi
    Kojima, Seiji
    Nakahata, Tatsutoshi
    PEDIATRIC TRANSPLANTATION, 2008, 12 (08) : 862 - 867
  • [42] PRELIMINARY RESULTS OF NON-ABLATIVE CONDITIONING (NAC) WITH BUSULFAN (Bu), FLUDARABINE (Flu) AND ALEMTUZUMAB FOLLOWED BY ALLOGENEIC STEM CELL TRANSPLANTATION (AlloSCT) TO INDUCE MIXED DONOR CHIMERISM IN PATIENTS WITH SICKLE CELL DISEASE (SCD)
    Bhatia, M.
    Baldinger, L.
    Billote, G.
    Morris, E.
    Bradley, M. B.
    George, D.
    Garvin, J.
    Satwani, P.
    Schwartz, J.
    Wolownik, K.
    Foley, S.
    Hawks, R.
    Baxter-Lowe, L. A.
    Cairo, M. S.
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2008, 14 (02) : 82 - 83
  • [43] Long-term follow-up of IV busulfan (Bu) with fludarabine (Flu) vs IV bu with cyclophosphamide (Cy) as pre (Allogeneic) transplant conditioning therapy forAML/MDS.
    De Lima, Marcos
    Wang, X.
    Thall, P. F.
    Couriel, D.
    Jones, R. B.
    Shpall, E. J.
    Popat, U.
    Giralt, S.
    Korbling, M.
    Champlin, R.
    Andersson, B. S.
    BLOOD, 2006, 108 (11) : 100A - 100A
  • [44] Clofarabine ± Fludarabine with IV Busulfan and Allogeneic Stem Cell Transplantation for Advanced Myeloid Leukemia (ML) and MDS
    Chu, Diem
    Valdez, Ben C.
    Fox, Patricia S.
    Thall, Peter
    Worth, Laura
    Popat, Uday R.
    Jones, Roy B.
    Shpall, Elizabeth J.
    Hosing, Chitra
    Alousi, Amin M.
    Rondon, Gabriela
    Kebriaei, Partow
    Champlin, Richard E.
    Andersson, Borje S.
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2014, 20 (02) : S152 - S153
  • [45] Antithymocyte globulin (ATG) as intensification of the conditioning regimen in pediatric patients undergoing stem cell transplantation (SCT).
    Yaniv, I
    Stein, J
    Goshen, J
    BONE MARROW TRANSPLANTATION, 1999, 23 : S180 - S180
  • [46] CLOFARABINE ± FLUDARABINE AND IV BUSULFAN WITH ALLOGENEIC STEM CELL TRANSPLANTATION FOR ADVANCED MYELOID LEUKEMIA (ML) AND MDS
    Andersson, B. S.
    Valdez, B. C.
    Thall, P. F.
    Wang, X.
    Worth, L. L.
    Popat, U.
    Alousi, A.
    Hosing, C.
    Jones, R. B.
    Shpall, E. J.
    de Lima, M.
    Champlin, R. E.
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2011, 17 (02) : S293 - S293
  • [47] Preliminary results of fludarabine, idarubicine and ARA-C as conditioning regimen for allogeneic stem cell transplantation.
    Lerner, D
    Pigneux, A
    Agape, P
    Lounici, A
    Fabéres, C
    Marit, G
    Cony-Makhoul, P
    Dazey, B
    Cousin, T
    Reiffers, J
    Boiron, JM
    BLOOD, 1998, 92 (10) : 352B - 352B
  • [48] ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANT (HSCT) FOR PATIENTS IN THE 6TH AND 7TH DECADES OF LIFE WITH AML OR MDS USING MYELOABLATIVE, REDUCED TOXICITY IV BUSULFAN/FLUDARABINE (BUFLU) CONDITIONING REGIMEN
    Alatrash, G.
    Andersson, B.
    Pelosini, M.
    Rondon, G.
    Qazilbash, M.
    Giralt, S.
    Silva, L. de Padua
    Hosing, C.
    Kebriaei, P.
    Zhang, W.
    Saliba, R.
    Champlin, R.
    de Lima, M.
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2009, 15 (02) : 106 - 106
  • [49] Myeloablative conditioning with fludarabine and iv-busulfan for allogeneic stem cell transplantation: a comparison with BU-CY2 in acute myeloid leukaemia
    Nacer, R. Ahmed
    Benakli, M.
    Talbi, A.
    Mehdid, F.
    Belhadj, R.
    Rahmoune, N.
    Ouali, D. Ait
    Baazizi, M.
    Hamladji, R. -M.
    BONE MARROW TRANSPLANTATION, 2011, 46 : S269 - S269
  • [50] TOLERABILITY AND OUTCOMES OF A TARGETED INTRAVENOUS BUSULFAN AND FLUDARABINE (T-BU/FLU) CONDITIONING REGIMEN FOR THE TREATMENT DE NOVO AND SECONDARY ACUTE MYELOID LEUKEMIA (AML)
    Fernandez, H. F.
    Perkins, J.
    Field, T.
    Alsina, M.
    Ayala, E.
    Kharfan-Dabaja, M.
    Ochoa, J. L.
    Perez, L.
    Raychaudburi, J.
    Anasetti, C.
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2009, 15 (02) : 62 - 63
12345